Location: Digital Event
Advancing Continuous Bioprocessing to Enhance Productivity, Rapid Scale-Up Capabilities & Product Quality.
Join Commercializing Continuous Processing in Pharma and Purolite Life Sciences for an exclusive virtual event exploring how to advance continuous bioprocessing to enhance productivity, rapid scale-up capabilities, and drug product quality.
Following success from small molecules and the FDA’s Emerging Technology initiative, the continuous bioprocessing market is poised to reach US$7.33 billion by 2027. Fueled by the pandemic disruption, drug developers and regulatory agencies have all shown commitments to invest, improve and implement this advanced manufacturing to ensure next gen biologics’ rapid scale-up for commercial production.
Featuring expert insights from Bristol-Myers Squibb, Janssen R&D, Purolite Life Sciences, and more, this is your definitive platform designed to help you benchmark against them and providing you with exclusive access to continuous bioprocessing think tank, hearing insights from leaders to help you accelerate implementation.
Over the last 5 years, the CCP team has been dedicated to this community, bringing real life case studies to help drug developers better understand the technology, science, and business cases for investing in continuous manufacturing.